Muthanna Medical Journal
Murtada Hafedh Hussein ¹, Marwa Mohammed Ali Jassim ², Ahmed Rafea Naje ²
² College of Dentistry, Al-Muthanna University, Al-Muthanna, Iraq.
Received 15 February 2023; revised 23 May 2023; accepted 30 May 2023, available online 07 June 2023.
Abstract
The chronic inflammatory disease rheumatoid arthritis (RA), which mostly affects the joints, is linked to considerable a lower lifestyle quality. For individuals Inhibitors of the Janus kinase (JAK), a recently formed family of oral tiny molecules medicines, are being used to treat RA patients who don't react to traditional therapy or biologic treatment, provide an alternative. The prevalence of RA varies greatly; investigations in several European nations have revealed rates ranging from 0.5% to 1.0%; research has showed that the RA incidence in Europe and In North America, it ranged from 0.5 to 1%. Many macrophages, tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1, IL-6, and IL-17, among others, are cytokines, are crucial in the development of disease; In addition to being stimulated by cytokines, osteoclasts also break down bone. There are several well-known risk factors for negative results, including illness activity is high, the early joint injury, the presence of autoantibodies, and early diagnosis is crucial to the efficiency of the therapy process. Biologics like Inhibitors of TNF-alpha, IL-1, IL-6, CD20, and cytotoxic T-lymphocyte associated antigen (CTLA)-4 (abatacept), as well as infliximab (etanercept, adalimumab), anakinra (anakinra), and tocilizumab (tocilizumab) are also available have altered the course of disease over the past few decades.
Keywords: Janus kinase inhibitor, Rheumatoid arthritis, Iraqi patients, TNF-alpha inhibitors, CD20 inhibitors